An Independent Validation Study of Candidate microRNAs as Predictive Biomarkers for Bevacizumab-based Therapy in Patients With Metastatic Colorectal Cancer
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00209805%3A_____%2F21%3A00078864" target="_blank" >RIV/00209805:_____/21:00078864 - isvavai.cz</a>
Alternative codes found
RIV/65269705:_____/21:00075841 RIV/00216224:14740/21:00120233
Result on the web
<a href="https://iv.iiarjournals.org/content/invivo/35/5/2809.full.pdf" target="_blank" >https://iv.iiarjournals.org/content/invivo/35/5/2809.full.pdf</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.21873/invivo.12567" target="_blank" >10.21873/invivo.12567</a>
Alternative languages
Result language
angličtina
Original language name
An Independent Validation Study of Candidate microRNAs as Predictive Biomarkers for Bevacizumab-based Therapy in Patients With Metastatic Colorectal Cancer
Original language description
Background/Aim: The monoclonal antibody bevacizumab is a standard drug used in combination with oxaliplatin (FOLFOX) or irinotecan (FOLFIRI) based chemotherapy in the first or second-line treatment of metastatic colorectal cancer (mCRC). Our previous study identified and subsequently validated 4 microRNAs in a small group of patients as predictors of the therapeutic response to bevacizumab combined with chemotherapy. The aim of this follow-up study is to confirm the predictive ability of these tissue miRNAs in a larger independent cohort of mCRC patients. Patients and Methods: The retrospective study included 92 patients with generalized-radically inoperable tumors treated with the combined therapy of bevacizumab/FOLFOX in a standard regimen. Results: Expression levels of candidate miRNA biomarkers (miR-92b3p, miR-3156-5p, miR-10a-5p and miR-125a-5p) were determined in tumor tissue specimens and statistically evaluated. MiR-92b-3p and miR-125a-5p were confirmed to be associated with radiological response according to RECIST criteria (p=0.005 and 0.05, respectively) and to be up-regulated in responders to bevacizumab/FOLFOX therapy. Higher levels of miR-92b-3p were also significantly associated with extended progression-free survival
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30204 - Oncology
Result continuities
Project
Result was created during the realization of more than one project. More information in the Projects tab.
Continuities
—
Others
Publication year
2021
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
IN VIVO
ISSN
0258-851X
e-ISSN
—
Volume of the periodical
35
Issue of the periodical within the volume
5
Country of publishing house
GR - GREECE
Number of pages
6
Pages from-to
2809-2814
UT code for WoS article
000691746000013
EID of the result in the Scopus database
2-s2.0-85113904648